结核病诊断与生物标志物进展(2020-2026):科学证据、推荐、差距与发展优先事项
本文综述2020至2025年结核病诊断与生物标志物研究的主要进展,这些进展为更新版WHO政策指南提供了依据,将结核病及耐药检测推荐整合于单一框架。数字化胸片联合计算机辅助检测成为WHO推荐的核心筛查分诊工具,低复杂度自动化核酸扩增检测等分散化分子诊断得到扩展。宿主血液转录组特征显示良好的短期预后与分诊性能,但尚无生物标志物满足WHO即时检测目标产品概况标准。
要点
- 数字化胸片联合计算机辅助检测被WHO推荐为核心筛查与分诊工具。
- 低复杂度自动化NAAT(如Xpert MTB/RIF Ultra和Truenat)支持分散化分子诊断。
- 舌拭子、粪、胃吸出物等非痰标本及痰池化策略改善少痰人群细菌学确认。
核心结论
- 2020至2025年结核病诊断与生物标志物研究取得重大进展,为WHO更新政策指南提供依据。
- WHO将结核病及耐药检测推荐整合于单一框架,协调不同人群和标本类型的筛查、诊断与耐药检测。
- 宿主血液转录组特征显示良好短期预后与分诊性能,但尚无生物标志物满足WHO即时检测目标产品概况标准。
研究设计与样本
- 本文为综述,汇总2020至2025年结核病诊断与生物标志物研究的科学证据、WHO推荐、差距及发展优先事项。
主要发现
- 数字化胸片 increasingly 由计算机辅助检测支持,现为WHO推荐的核心筛查与分诊工具,可提高病例发现和转诊确认检测的可及性。
- WHO推荐的快速诊断检测类别多样化部署扩展了分散化分子诊断,尤其是低复杂度自动化NAAT,包括Xpert MTB/RIF Ultra和Truenat平台。
- 低复杂度手动NAAT如结核环介导等温扩增及评估中的新兴近即时分子平台补充了上述检测。
- 最新WHO政策更新引入一类专为分散化使用设计的近即时NAAT,并纳入舌拭子等新标本类型及痰池化等规划创新。
- 在非痰标本(包括粪、胃吸出物和鼻咽样本)中扩大分子诊断应用并简化流程,改善了儿童和其他少痰人群的细菌学确认。
关键数值与推荐
- WHO推荐数字化胸片 increasingly 联合计算机辅助检测作为核心筛查与分诊工具。
- WHO推荐低复杂度自动化NAAT(包括Xpert MTB/RIF Ultra和Truenat)用于分散化分子诊断。
- WHO认可靶向下一代测序用于参考实验室层面的综合药敏试验。
- 尚无生物标志物满足WHO即时检测目标产品概况标准。
临床怎么用
- 在资源有限或分散化场景中,可优先采用WHO推荐的数字化胸片联合计算机辅助检测进行筛查与分诊。
- 对无法咳痰者,可考虑舌拭子等非痰标本进行分子检测以改善细菌学确认。
- 对HIV感染者尤其是晚期疾病患者,尿脂阿拉伯甘露聚糖检测可提高诊断率,但需注意性能局限。
- 在参考实验室层面,靶向下一代测序可用于综合耐药检测。
局限性
- 显著的性能、实施和公平性差距仍然存在。
- 尿脂阿拉伯甘露聚糖检测的性能局限限制其更广泛使用。
- 尚无生物标志物满足WHO即时检测目标产品概况标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lancet Microbe. 2027 Apr 27:101435. doi: 10.1016/j.lanmic.2026.101435. Online ahead of print. ABSTRACT Major advances in tuberculosis diagnostics and biomarker research from 2020 to 2025 have informed updated WHO policy guidance, consolidating recommendations for the detection of tuberculosis disease and drug resistance within a single framework. These recommendations align screening, diagnosis, and drug-resistance testing across populations and specimen types. Digital chest radiography, increasingly supported by computer-aided detection, is now a core WHO-recommended screening and triage tool, improving case detection and referral for confirmatory testing at scale. Decentralised molecular diagnosis has expanded through diversified deployment of WHO-recommended rapid diagnostic test classes, particularly low-complexity automated nucleic acid amplification tests (NAATs), including the Xpert MTB/RIF Ultra and Truenat platforms. These tests are complemented by low-complexity manual NAATs such as tuberculosis loop-mediated isothermal amplification and by emerging near point-of-care molecular platforms under evaluation. Latest WHO policy updates have also introduced a new class of near point-of-care NAATs designed for decentralised use, alongside novel specimen types such as tongue swabs for individuals unable to produce sputum, and programmatic innovations, including sputum pooling, to improve efficiency. Expanded use of molecular diagnostics across non-sputum specimens, including stool, gastric aspirate, and nasopharyngeal samples, together with simplified workflows, has improved bacteriological confirmation in children and other sputum-scarce populations. Rapid molecular drug-resistance testing has advanced with Xpert MTB/XDR, and targeted next-generation sequencing is now recognised as a WHO-endorsed approach for comprehensive drug-susceptibility testing at reference laboratory level. Urine lipoarabinomannan-based assays improve diagnostic yield in people with HIV, particularly those with advanced disease, although performance limitations constrain broader use. Substantial performance, implementation, and equity gaps remain. In parallel, host blood transcriptomic signatures show strong short-term prognostic and triage performance, and additional proteomic, metabolomic, cellular, imaging, and pathogen-derived biomarkers are advancing through clinical evaluation. However, no biomarker has yet met the WHO target product profile criteria for a point-of-care tes
引用
- 指南共识 · 支气管扩张与结核:Advances in tuberculosis diagnostics and biomarkers, 2020-26: scientific evidence, recommendations, gaps, and developmental priorities
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。